Led by Professor Jennifer Martin “Cannabinoids for Symptom Control in Advanced CanceR, an OpEn Label Prospective Clinical Trial in NSW” (CARE NSW) is a clinical trial comprising of a team of 14 Investigators from across NSW. A flagship study within the NHMRC Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), CARE NSW is funded by the NSW Government through the NSW Clinical Cannabis Medicines Program.
This trial will collect evidence to determine what dose and frequency of a range of cannabis medicines may be best to relieve the 3 major symptoms of advanced cancer – pain, and/or nausea and/or anorexia, in up to 600 patients with advanced patients across metropolitan and regional NSW.
It is hoped the information collected in this study will guide the future use of cannabis medicines to control symptoms in people with advanced cancer.
The range of cannabis medicines prescribed in CARE NSW are all oral oils that meet strict national and state regulatory requirements for prescribed cannabis medicines.
Currently CARE NSW is open and recruiting at Tamworth Hospital, as well as Orange Health Service, Chris O’Brien Lifehouse, Liverpool. Hospital, Tamworth Hospital, Prince of Wales Hospital, Westmead Hospital, Gosford and Wyong Hospitals, Macquarie University, Wollongong and Shoalhaven Hospitals, and St Vincent’s Hospital Sydney. Following delays due to COVID-19, several other sites across metropolitan and regional NSW are currently in the process of opening.
Further information about CARE NSW may be found here https://www.medicinalcannabis.nsw.gov.au/clinical-trials/advanced-cancer
